Skip to content
Case Report: PRaG 3.0 therapy for advanced cervical cancer with severe comorbidities
§Literature Feed

New onco-nephrology research

Recent papers on anti-cancer drug nephrotoxicity, immune-related kidney injury, and onco-nephrology — pulled from PubMed automatically as records are indexed, newest first. This is a discovery feed, not curated commentary.

80 recent articlesFeed updated Oct 1, 2026 RSS

Curated highlights

Monoclonal gammopathy of clinical significance: a guide for nephrologists

A guide to monoclonal gammopathy of clinical significance (MGCS) — the umbrella under which MGRS sits, covering clones that are pathogenic without meeting criteria for hematologic malignancy. The authors classify these disorders by the pathogenic mechanism of the paraprotein rather than by clonal burden, and cover the entities that reach nephrology from outside the kidney: POEMS syndrome, TEMPI syndrome, monoclonal gammopathy-associated systemic capillary leak syndrome, and hematologic autoantibody-mediated disorders.

Read more

Monoclonal gammopathy of undetermined significance (MGUS) is commonly encountered in older individuals. MGUS, by definition, is a benign finding where an expanded population of clonal plasma and B-cells produces a monoclonal antibody that is a biologically inactive. Even in patients with overt plasma cell neoplasms such as multiple myeloma, the monoclonal antibody is often a marker of disease burden but not pathogenic except in light chain cast nephropathy. However, there is a growing recognition that, in rare cases, clonal cells and/or monoclonal gammopathy not meeting criteria for hematologic malignancy can be pathogenic drivers of disease. These MGUS syndromes have been termed monoclonal gammopathies of clinical significance (MGCS), a larger umbrella under which sits the monoclonal gammopathies of renal significance (MGRS). In this review, we focus on MGCS entities beyond standard MGRS and provide a mechanism-based classification centered on the pathogenic nature of the paraprotein rather than on clonal disease burden. We highlight MGCS entities of relevance to nephrologists, including POEMS syndrome, TEMPI syndrome, monoclonal gammopathy-associated systemic capillary leak syndrome, and hematologic autoantibody-mediated disorders. Awareness and recognition of these rare processes are ultimately essential for accurate diagnosis and patient management.

PubMed 42545758

Rituximab as Rescue Therapy for Atezolizumab-Induced IgA Vasculitis

Kidney Medicine (Riaza Ortiz, Arriola-Montenegro, Sethi, Herrmann; online 25 Jul 2026). The first biopsy-confirmed report of IgA vasculitis with necrotizing and crescentic glomerulonephritis on the PD-L1 inhibitor atezolizumab — a phenotype well outside the acute interstitial nephritis that dominates checkpoint-inhibitor kidney injury. High-dose oral and intravenous corticosteroids gave only partial renal improvement; rituximab produced sustained stabilisation of kidney function alongside normalised TNF-alpha, IL-18 and soluble IL-2 receptor, and complete peripheral B-cell depletion. One patient, so it supports rituximab as rescue in corticosteroid-refractory disease rather than establishing it.

Drug profile

Latest from PubMed

  1. Case Report: PRaG 3.0 therapy for advanced cervical cancer with severe comorbidities

    Gu X, Xu M, Dai J · Frontiers in oncology · 2026

    Onco-nephPubMed 42819108 DOI
  2. FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation: a case report and review of the literature

    Saiki R, Katayama K, Matsui Y · CEN case reports · 2026 Sep 30

    Onco-nephPubMed 42816699 DOI
  3. BK Virus-Associated Hemorrhagic Cystitis in Nontransplanted Children With Hematological Malignancies: A Single-Center Case Series

    Morón-Cazalilla G, Pons-Espinal M, Alonso-Saladrigues A · Journal of pediatric hematology/oncology · 2026 Sep 30

    Onco-nephPubMed 42814566 DOI
  4. Immunotherapy of membranous nephropathy: strategic evolution from CD20 monoclonal antibodies to future vaccines

    Yu K, Xu X, Gao J · Frontiers in immunology · 2026

    Onco-nephPubMed 42812913 DOI
  5. Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review

    Allinovi M, Lomi J, Accinno M · Frontiers in immunology · 2026

    Onco-nephPubMed 42812566 DOI
  6. Gastrointestinal Manifestation of Light Chain Deposition Disease: Beware of the Snakeskin Duodenum

    Zhu A, Cheng J, Fiori J · ACG case reports journal · 2026 Oct

    Onco-nephPubMed 42808124 DOI
  7. Artesunate alleviates cisplatin-induced nephrotoxicity by regulating tryptophan metabolism and inhibiting ferroptosis

    Hu H, Zhang W, Wang H · Frontiers in pharmacology · 2026

    Onco-nephPubMed 42807112 DOI
  8. Rituximab as Rescue or Add-On Therapy for Relapsing or Refractory Lupus Nephritis: A Systematic Review and Meta-Analysis

    Wang X, Liang S, Sun X · Clinical and translational science · 2026 Oct

    Onco-nephPubMed 42806593 DOI
  9. Adult-Onset IgA Vasculitis With Concurrent Gastrointestinal and Possible Coronary Involvement

    Suleman M, Chauhan S, Chan A · Cureus · 2026 Sep

    Onco-nephPubMed 42799210 DOI
  10. A Case of Minimal Change Disease in a Patient Receiving Immune Checkpoint Inhibitor

    Liew MH, Xavier A, Chieng ACR · Cureus · 2026 Aug

    Onco-nephPubMed 42798545 DOI
  11. Association of the Preoperative CALLY Index with Acute Kidney Injury After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Comparison with Other Inflammatory and Immune-Nutritional Indices

    Şahin H, Ulusal Okyay G, Ayerden Ebinç F · Journal of clinical medicine · 2026 Sep 20

    Onco-nephPubMed 42796080 DOI
  12. Perioperative Fluid Management and Renal Protection in Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC): A Scoping Review

    Pasta G, L'Acqua C, Filetici N · Journal of clinical medicine · 2026 Sep 20

    Onco-nephPubMed 42796079 DOI
  13. Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy

    Gembillo G, Soraci L, Lo Cicero L · Journal of clinical medicine · 2026 Sep 17

    Onco-nephPubMed 42795985 DOI
  14. Rituximab Outcomes and Predictors of Treatment Failure in Primary Membranous Nephropathy: A Retrospective Cohort Study

    Güllülü Boz SE, Hunutlu FÇ, Çelik E · Journal of clinical medicine · 2026 Sep 11

    Onco-nephPubMed 42795840 DOI
  15. Immune Checkpoint Inhibitor Therapy and Risk of Glomerular Disease: A Large Propensity-Matched Cohort Study

    Tsai PH, Chang WC, Jhou HJ · Life (Basel, Switzerland) · 2026 Sep 21

    Onco-nephPubMed 42795441 DOI
  16. Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology

    Sena BF, Homo A, Fahy C · Cancers · 2026 Sep 10

    Onco-nephPubMed 42794904 DOI
  17. Biomarkers in Clear Cell Renal Cell Carcinoma: From Biological Association to Clinical Decision-Making

    Al Etri H, Al Zoghby L, Zoghbi MS · Genes · 2026 Sep 17

    Onco-nephPubMed 42793031 DOI
  18. Echinacoside Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating Bap1 to Inhibit Ferroptosis

    Chen L, Zhang M, Chi M · Biomedicines · 2026 Sep 20

    Onco-nephPubMed 42792866 DOI
  19. Clinical and immunological outcomes of rituximab-based, mycophenolate mofetil-based and cyclophosphamide-based treatment strategies for systemic lupus erythematosus with active kidney involvement from LOOPS registry

    Ueno M, Miyagawa I, Tanaka H · RMD open · 2026 Sep 25

    Onco-nephPubMed 42791028 DOI
  20. Rituximab in Pediatric Steroid-Resistant Nephrotic Syndrome: How Early is Early Enough?

    Gomez A, Oh J · Kidney international reports · 2026 Oct

    Onco-nephPubMed 42787721 DOI
  21. Biopsy-Confirmed Severe Acute Kidney Injury Requiring Emergent Hemodialysis After Eight Months of Alectinib Therapy

    Li JH, Cadavona JJP, Fagel C · Cureus · 2026 Aug

    Onco-nephPubMed 42787503 DOI
  22. Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: a systematic review and meta-analysis of 72,980 patients

    Pires IZ, Fujimura AY Jr, da Silva Gobbo MO · Cancer chemotherapy and pharmacology · 2026 Sep 24

    Onco-nephPubMed 42786231 DOI
  23. Renal Function Decline After (177)Lu-PSMA-617 Versus Taxane-Based Chemotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Propensity Score Analysis

    Sheheryar N, Nikanpour Y, Manohar S · Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026 Sep 24

    Onco-nephPubMed 42785953 DOI
  24. Drug-Induced Thrombotic Microangiopathy in Cancer: Can Kidney Biopsy Help Unravel This Highly Heterogeneous Pathologic Entity?

    Barbarini M, Herrmann SM · Kidney360 · 2026 Sep 1

    Onco-nephPubMed 42782826 DOI
  25. Severe hyponatremia following low-dose cyclophosphamide in a patient with breast cancer: a case report

    Cindoğlu Ç, Ağan FZ · International cancer conference journal · 2026 Oct

    Onco-nephPubMed 42781081 DOI
  26. Suspected Pembrolizumab-Associated Perinuclear Antineutrophil Cytoplasmic Antibody (p-ANCA) Vasculitis With Progressive Kidney Injury in a Patient With Metastatic Renal Cell Carcinoma and Limited Renal Reserve: A Diagnostic Challenge

    Goshtaseb R, Luu Y, Sarmosyan K · Cureus · 2026 Aug

    Onco-nephPubMed 42780982 DOI
  27. Does baseline proteinuria affect the efficacy of obinutuzumab in patients with primary membranous nephropathy and minimal change disease? a single-center retrospective study

    Li X, Zhang Y, Ke B · Frontiers in pharmacology · 2026

    Onco-nephPubMed 42780839 DOI
  28. Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- and Light-Chain Amyloidosis in a Patient With Systemic Lupus Erythematosus

    Patel R, Patel Y, Tallapally H · Cureus · 2026 Aug

    Onco-nephPubMed 42780369 DOI
  29. Blinatumomab as the first-line induction for ANCA-associated rapidly progressive glomerulonephritis

    Wang J, Yu Y, Li R · RMD open · 2026 Sep 23

    Onco-nephPubMed 42778331 DOI
  30. ADP-Ribosylation Factor Guanine Nucleotide Exchange Factor 3 Aggravates Cisplatin-Induced Acute Kidney Injury by Impairing Mitochondrial Fatty Acid Oxidation

    Wang L, Guo J, Zhao Y · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026 Sep 30

    Onco-nephPubMed 42776417 DOI
  31. Hematologic response assessment in monoclonal gammopathy of renal significance: critical appraisal of current criteria

    Domingo-González A, Cannata-Ortiz P, Fernández-Prado R · Frontiers in medicine · 2026

    Onco-nephPubMed 42774073 DOI
  32. Severe, reversible alectinib-induced acute kidney injury requiring dialysis in an elderly patient with metastatic non-small cell lung cancer

    Rosa R, Sequeira T, Lérias S · BMJ case reports · 2026 Sep 22

    Onco-nephPubMed 42772921 DOI
  33. A machine-learning-derived online prediction model based on inflammatory and nutritional composite indicators for acute kidney injury in sepsis patients with multiple myeloma

    Zhang Q, Xin Q, Guo H · Frontiers in nutrition · 2026

    Onco-nephPubMed 42769257 DOI
  34. Noncrystalline light-chain proximal tubulopathy: a retrospective study from a single institute of China

    Yao JQ, Wang YH, Zhang X · Renal failure · 2026 Dec

    Onco-nephPubMed 42768862 DOI
  35. Glucocorticoids combined with rituximab treatment for IgG4-related tubulointerstitial nephritis with diabetic nephropathy: a case report

    Wang T, Zhang J, Xu Y · Open medicine (Warsaw, Poland) · 2026 Jan

    Onco-nephPubMed 42763610 DOI
  36. LAMA5 pathogenic variant uncovers a novel autoantigen in membranous nephropathy

    Xiao H, Yin H, Shi Y · Genes & diseases · 2027 Jan

    Onco-nephPubMed 42763546 DOI
  37. Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement

    Juanet C, Hassi I, Cara A · Kidney international reports · 2026 Oct

    Onco-nephPubMed 42761229 DOI
  38. Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis

    Qin Q, Ostendorf L, Wells SL · Kidney international reports · 2026 Oct

    Onco-nephPubMed 42756960 DOI
  39. Transient global aphasia associated with daratumumab in monoclonal immunoglobulin light chain deposition disease

    Tuttle Z, Gardiner S, Trost N · Internal medicine journal · 2026 Sep 17

    Onco-nephPubMed 42755232 DOI
  40. Octreotide mitigates cisplatin-induced nephrotoxicity through coordinated modulation of the miR-34a/SIRT1 axis and downstream apoptotic, inflammatory, and fibrotic pathways

    Ghoneim ME, El Banna YY, Noureldin MH · Life sciences · 2026 Sep 17

    Onco-nephPubMed 42753908 DOI
  41. Pursuing the optimal strategy for immunosuppression discontinuation in children treated with rituximab for frequently relapsing, steroid-dependent nephrotic syndrome

    Malakasioti G, Tullus K, Chan EY · Pediatric nephrology (Berlin, Germany) · 2026 Sep 17

    Onco-nephPubMed 42752635 DOI
  42. Intratubular light chain amyloidosis: a comprehensive analysis of disease spectrum and clinicopathological characteristics

    Wang X, Yuan Y, Zhou D · Clinical kidney journal · 2026 Sep

    Onco-nephPubMed 42746147 DOI
  43. Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe kidney involvement

    Chaudhari N, Ul Hussain A, Quill L · Clinical kidney journal · 2026 Sep

    Onco-nephPubMed 42741535 DOI
  44. Cellular Recovery and Therapeutic Rechallenge After Cancer Therapy-Induced Kidney Injury: Mechanistic Insights and Clinical Implications

    Dotsu Y, Akagi K, Honda N · Cells · 2026 Aug 28

    Onco-nephPubMed 42738857 DOI
  45. Distinct Predictors of Early Postoperative and Long-Term Renal Function Decline Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

    Matsumoto S, Waseda Y, Kobayashi M · International journal of urology : official journal of the Japanese Urological Association · 2026 Sep

    Onco-nephPubMed 42735286 DOI
  46. Pharmacological characterization and nephroprotective potential of venoms from three egyptian scorpion species

    Megaly AMA, Miyashita M, Alqahtani AR · Frontiers in pharmacology · 2026

    Onco-nephPubMed 42729245 DOI
  47. Long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced NSCLC: FLAURA2

    Planchard D, Jänne PA, Yang JC · Lung cancer (Amsterdam, Netherlands) · 2026 Sep 14

    Onco-nephPubMed 42728193 DOI
  48. POEMS syndrome presenting as presumed chronic glomerulonephritis with a 1-year delay in diagnosis: a case report

    Liu L, Li M, Li F · Frontiers in medicine · 2026

    Onco-nephPubMed 42723812 DOI
  49. Progressive multifocal leukoencephalopathy during bispecific antibody therapy in multiple myeloma: from immune dysfunction to early recognition. Comment on: "Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple myeloma"

    Facchinelli D, Pagano L · Haematologica · 2026 Sep 10

    Onco-nephPubMed 42719974 DOI
  50. Obinutuzumab for Rituximab-Intolerant Minimal Change Disease: A Case Report and Review of Recent Literature

    Shan HY · Cureus · 2026 Aug

    Onco-nephPubMed 42719894 DOI
  51. Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: A Single-Centre Study

    Kuppa J, Rao N, Juneja R · Asia-Pacific journal of clinical oncology · 2026 Sep 9

    Onco-nephPubMed 42717531 DOI
  52. Immunotactoid Glomerulopathy Diagnosed by a Repeat Kidney Biopsy After Initially Non-diagnostic Electron Microscopic Findings: A Case Report

    Yamada M, Nagashima M, Aoki K · Internal medicine (Tokyo, Japan) · 2026 Sep 8

    Onco-nephPubMed 42716754 DOI
  53. A Step Forward - Obinutuzumab for Membranous Nephropathy

    Soler MJ · The New England journal of medicine · 2026 Sep 10

    Onco-nephPubMed 42715567 DOI
  54. Efficacy and safety of eculizumab-combined therapy for patients with anti-GBM disease

    Lang X, Hong X, Wu W · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026 Sep 9

    Onco-nephPubMed 42714831 DOI
  55. Allogeneic CD19 CAR-NK cell therapy for a patient with relapsed and refractory lupus nephritis

    Tang Y, Wang Y, Shi W · Arthritis research & therapy · 2026 Sep 8

    Onco-nephPubMed 42711699 DOI
  56. Accelerated desensitization enables HLA-incompatible deceased donor kidney transplant in a highly sensitized pediatric recipient

    Pande N, Alabdulqader M, Gaudreault-Tremblay MM · Human immunology · 2026 Sep 7

    Onco-nephPubMed 42705155 DOI
  57. Subcutaneous Daratumumab in Recurrent Posttransplant Focal Segmental Glomerulosclerosis: A Report of 2 Cases

    Aleš Rigler A, Belčič Mikič T, Bošnjak M · Kidney medicine · 2026 Sep

    Onco-nephPubMed 42698729 DOI
  58. Early-stage IgM kappa proliferative glomerulonephritis with monoclonal immunoglobulin deposition presenting with atypical renal insufficiency: a case report and literature review

    Cui A, Yu J, Pan T · Frontiers in medicine · 2026

    Onco-nephPubMed 42698465 DOI
  59. Rituximab-Based Therapy in IgA Nephropathy With Crescents: A Comparative Study

    Berti GM, Tondolo F, Iandolo A · Clinical therapeutics · 2026 Sep 4

    Onco-nephPubMed 42697788 DOI
  60. Outcome of Children Treated with Rituximab for Steroid-Resistant Nephrotic Syndrome: Renal Histopathology as a Response Marker

    Alsalloum AA, Farhat AH, Alherbish · Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia · 2026 Nov 1

    Onco-nephPubMed 42690101 DOI
  61. A case of anti-nephrin antibody-positive, steroid-dependent nephrotic syndrome with successful discontinuation of immunosuppressants following rituximab

    Shinzato K, Hayashi N, Akai R · Oxford medical case reports · 2026 Sep

    Onco-nephPubMed 42688926 DOI
  62. Management strategies for post-transplant IgA nephropathy in kidney transplant recipients: a scoping review

    Bell S, Toal M, McClure M · BMC nephrology · 2026 Aug 20

    Onco-nephPubMed 42687161 DOI
  63. Comparison of efficacy and safety among four therapeutic regimens in primary membranous nephropathy with high anti-PLA2R antibody titers: a single-center retrospective cohort study

    Huang Y, Meng X, Wu S · BMC nephrology · 2026 Aug 31

    Onco-nephPubMed 42687143 DOI
  64. Efficacy and safety of telitacicept for rituximab-refractory membranous nephropathy

    He X, Huang Y, Qu Z · International urology and nephrology · 2026 Sep 3

    Onco-nephPubMed 42686924 DOI
  65. Obinutuzumab Compared to Cyclosporine with Steroids for the Treatment of Primary Membranous Nephropathy: A Propensity Score-Matched Analysis

    Hu X, Zhang M, Xu L · Kidney360 · 2026 Sep 2

    Onco-nephPubMed 42684841 DOI
  66. Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report

    Nawata T, Shibuya M, Asami-Noyama M · CEN case reports · 2026 Sep 2

    Onco-nephPubMed 42684586 DOI
  67. Low incidence of profound agranulocytosis after rituximab combined with prolonged low-dose prednisolone in children with complicated nephrotic syndrome

    Tanimoto R, Fujinaga S, Morishita T · Pediatric nephrology (Berlin, Germany) · 2026 Sep 2

    Onco-nephPubMed 42684401 DOI
  68. Which patients should switch from rituximab to obinutuzumab in refractory nephrotic syndrome?

    Fujinaga S, Ono T, Saito A · Pediatric nephrology (Berlin, Germany) · 2026 Sep 1

    Onco-nephPubMed 42680932 DOI
  69. Assessment of NGAL, eGFR, and tubular injury markers for early detection of chemotherapy-induced nephrotoxicity in pediatric oncology patients

    Markova P, Yaneva A, Spasova M · Folia medica · 2026 Aug 31

    Onco-nephPubMed 42677770 DOI
  70. Nintedanib-Associated Glomerular Endothelial Injury With Secondary Collapsing Focal Segmental Glomerulosclerosis: Potential Role of Sodium-Glucose Cotransporter 2 Inhibition

    Furuto Y, Hashimoto H, Yoshino D · Nephrology (Carlton, Vic.) · 2026 Sep

    Onco-nephPubMed 42674550 DOI
  71. Protective Effects of Luteolin Against Cisplatin-Induced Hepatic and Renal Toxicity: Biochemical and Cellular Evidence

    Temiz Ö, Kizilyildirim S, Ozdemir-Sanci T · Journal of biochemical and molecular toxicology · 2026 Sep

    Onco-nephPubMed 42671218 DOI
  72. Chronic Kidney Disease in Children Within Five Years After Ifosfamide Chemotherapy for Childhood Cancer: A Dutch Pediatric Oncology Cohort Study

    Pitlo L, Wens FSPL, Raymakers-Janssen PAMA · Cancer medicine · 2026 Sep

    Onco-nephPubMed 42670233 DOI
  73. Single-cell transcriptomic signatures of T cells associated with rituximab responsiveness in idiopathic nephrotic syndrome

    Koshi-Ito E, Watanabe Y, Onogi C · iScience · 2026 Sep 18

    Onco-nephPubMed 42668630 DOI
  74. Infliximab for the Treatment of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury

    Patel RR, Myers KE, Mirsky MM · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026 Aug 29

    Onco-nephPubMed 42667383 DOI
  75. Low-dose daratumumab and bortezomib for the treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a case report

    Zhu J, Zhang L, Zhao H · Frontiers in medicine · 2026

    Onco-nephPubMed 42666249 DOI
  76. Longitudinal Immunophenotypic Changes in Refractory Lupus Nephritis After B-cell Depletion: A 25-year Case Study

    Chen CC, Lu JW, Ho YJ · In vivo (Athens, Greece) · 2026 Sep-Oct

    Onco-nephPubMed 42665415 DOI
  77. Immune Checkpoint Inhibitor-Associated Acute Kidney Injury

    Puttamreddy SM, Khalid Y, Tendulkar K · JCO oncology practice · 2026 Aug 27

    Onco-nephPubMed 42659599 DOI
  78. Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy

    Georgopoulos C, Stamellou E, Duni A · International journal of molecular sciences · 2026 Aug 13

    Onco-nephPubMed 42653236 DOI
  79. Hesperetin loaded fucoidan selenium nanoparticles alleviate cisplatin induced acute kidney injury via antioxidant and cGAS STING pathway regulation

    Long L, Zhang Y, Xiao J · Discover nano · 2026 Aug 25

    Onco-nephPubMed 42640362 DOI
  80. Perilipin 2 drives cisplatin-induced acute kidney injury in young but not aged kidneys

    Zhu S, Dai C, Zheng K · American journal of physiology. Renal physiology · 2026 Sep 1

    Onco-nephPubMed 42581421 DOI
Follow the feed

Get the week's new onco-nephrology papers by email every Monday, or subscribe via RSS.

Article metadata via PubMed / NLM. This automated feed surfaces recent literature by search query — inclusion is not endorsement, and titles are not screened for clinical relevance. Medical-education content only — not medical advice.